A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

OBJECTIVE: The aim of this multi-institutional non randomized phase II trial was to determine the efficacy and safety of single agent aflibercept (VEGF Trap), a recombinant fusion protein that blocks multiple vascular endothelial growth factor isoforms, in women with gynecologic soft tissue sarcoma....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mackay, HJ, Buckanovich, RJ, Hirte, H, Correa, R, Hoskins, P, Biagi, J, Martin, LP, Fleming, GF, Morgan, R, Wang, L, Polintan, R, Oza, AM
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3303987/
https://ncbi.nlm.nih.gov/pubmed/22138373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2011.11.042
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars